Caplin Point Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Caplin Steriles (CSL), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) Foscavir Injection from Clinigen Healthcare, (NDA 020068).

Foscarnet Sodium Injection is an antiviral medication used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. According to IQVIATM (IMS Health), Foscarnet Sodium Injection, (6000 mg/250 mL Infusion Bag) had US sales of approximately $15 million for the 12-month period ending March 2026.

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.

Net profit of Caplin Point Laboratories rose 19.32% to Rs 170.11 crore in the quarter ended March 2026 as against Rs 142.57 crore during the previous quarter ended March 2025. Sales rose 19.45% to Rs 600.16 crore in the quarter ended March 2026 as against Rs 502.45 crore during the previous quarter ended March 2025.

For the full year,net profit rose 19.57% to Rs 641.24 crore in the year ended March 2026 as against Rs 536.31 crore during the previous year ended March 2025. Sales rose 12.89% to Rs 2187.19 crore in the year ended March 2026 as against Rs 1937.47 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.